Cost-effectiveness analysis of treating patients with ntrk-positive cancer with the histology-independent therapy entrectinib
<p><strong>Objectives</strong><br> This study tackles several challenges of evaluating histology-independent treatments using entrectinib as an example. Histology-independent treatments are provided based on genetic marker(s) of tumors, regardless of the tumor type. We evalua...
Main Authors: | Huygens, S, Vellekoop, H, Versteegh, M, Santi, I, Szilberhorn, L, Zelei, T, Nagy, B, Tsiachristas, A, Koleva-Kolarova, R, Wordsworth, S, Rutten-van Mölken, M |
---|---|
Other Authors: | HEcoPerMed consortium |
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2022
|
Similar Items
-
Guidance for the harmonisation and improvement of economic evaluations of personalised medicine
by: Vellekoop, H, et al.
Published: (2021) -
Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems
by: Koleva-Kolarova, R, et al.
Published: (2023) -
Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries
by: Szilberhorn, L, et al.
Published: (2023) -
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation
by: Koleva-Kolarova, R, et al.
Published: (2023) -
Financing and reimbursement models for personalised medicine: A systematic review to identify current models and future options
by: Koleva-Kolarova, R, et al.
Published: (2022)